Novo Nordisk

2011-03-15T17:48:37Z

2011-03-15T17:48:37Z

Novo Nordisk receives approval for Victoza® in China

Novo Nordisk announced today that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes.

Further information:

Media: Investors:
   
Mike Rulis Klaus Bülow Davidsen
Tel: (+45) 4442 3573 Tel: (+45) 4442 3176
mike@novonordisk.com   klda@novonordisk.com



Jannick Lindegaard
  Tel: (+45) 4442 4765
  jlis@novonordisk.com   


In North America: In North America:
Ken Inchausti Hans Rommer
Tel: (+1) 609 786 8316 Tel: (+1) 609 919 7937
kiau@novonordisk.com   hrmm@novonordisk.com  
Company Announcement no 16 2011